Last reviewed · How we verify
NCT03432299: RFAforPTMC
Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma
NA trial testing RFA for PTMC in Papillary Thyroid Microcarcinoma in 100 participants. Status unknown.
31 July 2023
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 16 April 2018 |
| Primary completion | 31 July 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- RFA for PTMC
Conditions studied
- Papillary Thyroid Microcarcinoma — all drugs for Papillary Thyroid Microcarcinoma →
- Thyroid Cancer — all drugs for Thyroid Cancer →
Sponsor
Seoul National University Hospital
Who can join
Adults 19 to 60, any sex, with Papillary Thyroid Microcarcinoma or Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center prospective clinical trial with regard to efficacy and safety of radiofrequency ablation of papillary thyroid microcarcinoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Prospective Clinical Trial of Radiofrequency Ablation in Patients with Low-Risk Unifocal Papillary Thyroid Microcarcinoma Favoring Active Surveillance Over Surgery.
Lee JY, Na DG, Sim JS, Sung JY, et al · · 2024 · cited 6× · PMID 39212950 · DOI 10.1089/thy.2024.0098
Verify or expand the search:
- PubMed search for NCT03432299
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Papillary Thyroid Microcarcinoma
Currently open trials in the same condition.
- NCT07054229 — Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhance · recruiting
- NCT06333587 — Minimally Invasive Treatments of the Thyroid · recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03432299 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 26 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03432299.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing